Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
(WorldNews Business)

WHIPPANY, N.J.--(BUSINESS WIRE)--Jan 21, 2020-- Bayer will present new research from the Company´s oncology portfolio, including Stivarga ® (regorafenib) and Vitrakvi ® (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California. The presentations will feature data on Stivarga in hepatocellular carcinoma (HCC) and gastric and colorectal cancers, as well as Vitrakvi in gastrointestinal cancer. Bayer continues to explore the possibility of Stivarga in additional indications and settings. At this year´s ASCO GI, new Phase 1b data of regorafenib plus pembrolizumab for first-line treatment...